Bayer is finally removing the remaining supplies of Trasylol from the U.S. market after a long-awaited Canadian study confirmed yet again that the anti-bleeding drug is dangerous.
On May 14, the BART study was published in the New England Journal of Medicine. Researchers found that heart surgery patients who were given Trasylol were 53 percent more likely to die than patients who were given cheaper blood clotting drugs.
That same day, Bayer notified the U.S. Food and Drug Administration that it will begin removing remaining Trasylol stock from the American market, most of which can be found in warehouses and with doctors and hospitals.
This should have been done a long time ago. Since 2006, three studies have linked Trasylol to an increased risk for kidney damage, stroke and death. If Bayer had removed the drug from the market when it learned of the health dangers, it is estimated that 22,000 lives could have been saved.
My law firm currently represents several Trasylol victims and their families in lawsuits against Bayer. The lawyers of Carey, Danis & Lowe are experienced in helping people injured by Trasylol. We will seek compensation for past and future medical expenses, past and future wages, pain and suffering, disability and other damages. We also represent family members in wrongful death cases.
We offer a free initial consultation for victims harmed pharmaceutical products. If you cannot make it to our office, we will come to you at the hospital or your home.
